I. AMENDMENTS

In the claims:

58. (Twice Amended) A method for inhibiting the proliferation of a pathological hyperproliferative cell comprising contacting the cell with an L- or D- isomer of the formula:



wherein R_1 is an electrophilic leaving group; or a compound of the formula:



wherein n is an integer from 1 to 10; wherein A is a phosphoryl or phosphoramidatyl, or a compound of the formula:



wherein Q is selected from the group consisting of a 5' substituted masked phosphoryl, a phosphoryl or phosphoramidatyl moiety selected from the group consisting of sugar; thio-sugar; carbocyclic; acyclic analogs and derivatives of a sugar, a thio-sugar or derivatives, analogs and pharmaceutically acceptable salts thereof.

62. (Twice Amended) A compound of the formula:



wherein:

R^1 is of the formula:



wherein n is from 1 to 10 and R^2 is selected from the group consisting of:

an unsaturated hydrocarbyl group;

an aromatic hydrocarbyl; and,

a heteroaromatic;

R^3 is selected from the group consisting of:





wherein R^5 may be the same or different and is independently a linear or branched alkyl group having from 1 to 10 carbon atoms, or a cycloalkyl group having from 3 to 10 carbon atoms;

wherein n is an integer from 1 to 10;

wherein m is 0 or 1;

wherein R^4 is a toxophore selected from the group consisting of:





C2 cont'd











and



C2 cont'd

wherein X is -Cl, -Br, -I, or other potent leaving group;

wherein Y is independently -H or -F;

wherein Z is independently -O- or -S-;

wherein Q is selected from the group consisting of:









and



C2 concld

wherein R^6 is independently -H, -OH, -OC(=O)CH_3, or -O-Rg wherein Rg is a hydroxyl protecting group other than acetyl; and,

wherein R^7 is a masked phosphate group, or a phosphoramidatyl group;

and wherein said compound may be in any enantiomeric, diasteriomeric, or stereoisomeric form, consisting of a D-form, L-form, α-anomeric form, and β-anomeric form.

63. (Amended) A compound according to claim 62, wherein Q is:

C3